Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00054639 · OUTCOME

Number of Patients With Objective Response

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · Source last updated 2014-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
2 months following study treatment

What was measured

Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment

Analysis population: Analysis was per protocol. Of the 48 participants enrolled, only 42 were evaluable for response.

Groups in this outcome

Oblimersen + Rituximab

Oblimersen 3 mg/kg/day continuous intravenous infusion daily for 7 days on alternated weeks on week 1, 3 and 5 (days 1 through 7, 15 through 21, and 29 through 35); Rituximab 375 mg/m2 intravenous infusion for six doses on days 3, 8,15, 22, 29, and 36.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Oblimersen + Rituximab42

Reported measurements

Complete Responses
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Oblimersen + Rituximab10Not reportedNot reportedNot reportedNot reported
Partial Responses
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Oblimersen + Rituximab8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Complete Responses
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Partial Responses
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    units
    Participants
description
Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment
groups
  1. description
    Oblimersen 3 mg/kg/day continuous intravenous infusion daily for 7 days on alternated weeks on week 1, 3 and 5 (days 1 through 7, 15 through 21, and 29 through 35); Rituximab 375 mg/m2 intravenous infusion for six doses on days 3, 8,15, 22, 29, and 36.
    id
    OG000
    title
    Oblimersen + Rituximab
param Type
NUMBER
population Description
Analysis was per protocol. Of the 48 participants enrolled, only 42 were evaluable for response.
reporting Status
POSTED
time Frame
2 months following study treatment
title
Number of Patients With Objective Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice